Poseida Therapeutics Q1 2024 Adj EPS $(0.25) Beats $(0.42) Estimate, Sales $28.14M Beat $11.67M Estimate
Portfolio Pulse from Benzinga Newsdesk
Poseida Therapeutics (NASDAQ:PSTX) reported Q1 2024 adjusted EPS of $(0.25), surpassing the $(0.42) estimate, with sales of $28.14M exceeding the $11.67M forecast. This represents a 172.09% increase in sales compared to the same period last year.
May 14, 2024 | 8:26 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Poseida Therapeutics reported a significant beat on both EPS and sales estimates for Q1 2024, with a notable year-over-year sales increase.
Beating both EPS and sales estimates significantly, especially with such a substantial year-over-year sales growth, is likely to be viewed positively by investors. This could lead to increased investor confidence and potentially drive up the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100